MX2023002439A - Composiciones immunogénicas y usos de las mismas. - Google Patents
Composiciones immunogénicas y usos de las mismas.Info
- Publication number
- MX2023002439A MX2023002439A MX2023002439A MX2023002439A MX2023002439A MX 2023002439 A MX2023002439 A MX 2023002439A MX 2023002439 A MX2023002439 A MX 2023002439A MX 2023002439 A MX2023002439 A MX 2023002439A MX 2023002439 A MX2023002439 A MX 2023002439A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic compositions
- immunogenic polypeptides
- encoding
- pharmaceutical preparations
- provides compositions
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063074428P | 2020-09-03 | 2020-09-03 | |
US202063125769P | 2020-12-15 | 2020-12-15 | |
US202163191020P | 2021-05-20 | 2021-05-20 | |
PCT/US2021/049077 WO2022051629A1 (en) | 2020-09-03 | 2021-09-03 | Immunogenic compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002439A true MX2023002439A (es) | 2023-05-09 |
Family
ID=77951867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002439A MX2023002439A (es) | 2020-09-03 | 2021-09-03 | Composiciones immunogénicas y usos de las mismas. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4208196A1 (he) |
JP (1) | JP2023542492A (he) |
CN (1) | CN116157148A (he) |
AU (1) | AU2021336976A1 (he) |
CA (1) | CA3193746A1 (he) |
IL (1) | IL300947A (he) |
MX (1) | MX2023002439A (he) |
TW (1) | TW202218669A (he) |
WO (1) | WO2022051629A1 (he) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023182948A1 (en) * | 2022-03-21 | 2023-09-28 | Bio Adventure Co., Ltd. | Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression |
WO2023235749A2 (en) * | 2022-06-01 | 2023-12-07 | Flag Bio, Inc. | Rna adjuvants, methods and uses thereof |
WO2023239704A2 (en) * | 2022-06-07 | 2023-12-14 | University Of South Florida | Preventing alu sines-mediated pathologies |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US99823A (en) | 1870-02-15 | Improved indigo soap | ||
WO1992001813A1 (en) | 1990-07-25 | 1992-02-06 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
US5426180A (en) | 1991-03-27 | 1995-06-20 | Research Corporation Technologies, Inc. | Methods of making single-stranded circular oligonucleotides |
WO1993014218A1 (en) | 1992-01-13 | 1993-07-22 | Duke University | Enzymatic rna molecules |
US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5766903A (en) | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
US5849727A (en) | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
JP4656675B2 (ja) | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | 脂質小胞への荷電した治療剤の高率封入 |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US6210931B1 (en) | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
JP4371812B2 (ja) | 2001-09-28 | 2009-11-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | マイクロrna分子 |
WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
JP4380411B2 (ja) | 2004-04-30 | 2009-12-09 | 澁谷工業株式会社 | 滅菌方法 |
JP5292572B2 (ja) | 2004-12-27 | 2013-09-18 | サイレンス・セラピューティクス・アーゲー | コーティングされた脂質複合体およびそれらの使用 |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
JP2009519033A (ja) | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
US20100168034A1 (en) | 2006-02-20 | 2010-07-01 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
DE112007000074T5 (de) | 2006-07-10 | 2009-04-02 | Memsic Inc., Andover | System zum Erfassen einer Gierrate unter Verwendung eines Magnetfeldsensors sowie tragbare elektronische Vorrichtungen unter Verwendung hiervon |
JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | 1本鎖環状rnaおよびその製造方法 |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
EA020312B1 (ru) | 2008-10-20 | 2014-10-30 | Элнилэм Фармасьютикалз, Инк. | Композиции и способы для ингибирования экспрессии транстиретина |
CN104910025B (zh) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | 氨基醇类脂质和其用途 |
WO2010054384A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Lipids and compositions for the delivery of therapeutics |
KR102042721B1 (ko) | 2008-11-10 | 2019-11-11 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
WO2010084371A1 (en) | 2009-01-26 | 2010-07-29 | Mitoprod | Novel circular interfering rna molecules |
KR20230098713A (ko) | 2009-06-10 | 2023-07-04 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
JP5766188B2 (ja) | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 固形腫瘍に治療剤を送達するための脂質製剤 |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
EP2467357B1 (en) | 2009-08-20 | 2016-03-30 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
US20130022649A1 (en) | 2009-12-01 | 2013-01-24 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
EP2526113B1 (en) | 2010-01-22 | 2016-08-10 | Sirna Therapeutics, Inc. | Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry |
US20120315324A1 (en) | 2010-02-05 | 2012-12-13 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
CA2799091A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
EP2575764B1 (en) | 2010-06-03 | 2017-04-19 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
NZ704191A (en) | 2010-06-14 | 2016-05-27 | Hoffmann La Roche | Cell-penetrating peptides and uses therof |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
HRP20220695T1 (hr) | 2010-08-31 | 2022-07-08 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rnk kodirane za imunogen |
EP3144015B1 (en) | 2010-09-20 | 2021-06-02 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
AU2011307277A1 (en) | 2010-09-30 | 2013-03-07 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
JP2013545727A (ja) | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
US9617461B2 (en) | 2010-12-06 | 2017-04-11 | Schlumberger Technology Corporation | Compositions and methods for well completions |
DK3202760T3 (da) | 2011-01-11 | 2019-11-25 | Alnylam Pharmaceuticals Inc | Pegylerede lipider og deres anvendelse til lægemiddelfremføring |
RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
JP6250543B2 (ja) | 2011-09-27 | 2017-12-20 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | ジ脂肪族置換peg化脂質 |
CN107522664B (zh) | 2011-10-27 | 2021-03-16 | 麻省理工学院 | 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物 |
WO2013070324A1 (en) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
CN103930398B (zh) | 2011-11-18 | 2016-08-24 | 日油株式会社 | 具有改进的细胞内动力学的阳离子脂质 |
CA2856742A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US9463247B2 (en) | 2011-12-07 | 2016-10-11 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
EP2792367A4 (en) | 2011-12-12 | 2015-09-30 | Kyowa Hakko Kirin Co Ltd | LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS |
WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
EP3988104A1 (en) | 2012-02-24 | 2022-04-27 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
EP2830594B1 (en) | 2012-03-27 | 2018-05-09 | Sirna Therapeutics, Inc. | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY |
EA030650B1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
US20160151284A1 (en) | 2013-07-23 | 2016-06-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
KR102096796B1 (ko) | 2013-10-22 | 2020-05-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 전달을 위한 지질 제형 |
AU2014348212C1 (en) | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
US9365610B2 (en) | 2013-11-18 | 2016-06-14 | Arcturus Therapeutics, Inc. | Asymmetric ionizable cationic lipid for RNA delivery |
WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
US10869898B2 (en) | 2014-04-01 | 2020-12-22 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
WO2016036735A1 (en) | 2014-09-05 | 2016-03-10 | The Johns Hopkins University | Liposome-based mucus-penetrating particles for mucosal delivery |
WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
RS64331B1 (sr) | 2015-06-19 | 2023-08-31 | Massachusetts Inst Technology | Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
AU2016288643A1 (en) | 2015-07-02 | 2018-02-22 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer |
EP3736261B1 (en) | 2015-09-17 | 2023-10-11 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
CA3003055C (en) | 2015-10-28 | 2023-08-01 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
CA3010510A1 (en) | 2016-01-11 | 2017-07-20 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
US20190136231A1 (en) | 2016-03-30 | 2019-05-09 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
JP2019536793A (ja) | 2016-12-02 | 2019-12-19 | ルビウス セラピューティクス, インコーポレイテッド | 固形腫瘍に浸透させるための細胞系に関連する組成物および方法 |
JP7317706B2 (ja) | 2016-12-14 | 2023-07-31 | リガンダル インコーポレイテッド | 核酸およびタンパク質ペイロード送達のための方法および組成物 |
BR112019016951A2 (pt) | 2017-02-17 | 2020-05-26 | Rubius Therapeutics, Inc. | Células eritroides funcionalizadas |
JP7395355B2 (ja) | 2017-05-08 | 2023-12-11 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | 膜融合を促進するための組成物およびその使用 |
EP3679148A4 (en) | 2017-09-08 | 2021-06-09 | Generation Bio Co. | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL CAPSIDE-FREE DNA VECTORS |
CA3077413A1 (en) | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | Formulations |
SG11202002562QA (en) | 2017-09-29 | 2020-04-29 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing |
BR112020011670A2 (pt) | 2017-12-15 | 2020-11-17 | Flagship Pioneering Innovations Vi, Llc. | composições compreendendo polirribonucleotídeos circulares e seus usos |
US10736957B2 (en) * | 2017-12-19 | 2020-08-11 | President And Fellows Of Harvard College | Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences |
AU2019265018A1 (en) | 2018-05-11 | 2020-11-26 | Beam Therapeutics Inc. | Methods of suppressing pathogenic mutations using programmable base editor systems |
AR116016A1 (es) | 2018-08-24 | 2021-03-25 | Flagship Pioneering Innovations Vi Llc | Métodos para fabricar paquetes mensajeros vegetales |
JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
AU2019384557A1 (en) | 2018-11-21 | 2021-06-10 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
KR20220005039A (ko) | 2019-04-25 | 2022-01-12 | 인텔리아 테라퓨틱스, 인크. | 이온화 가능한 아민 지질 및 지질 나노입자 |
EP3920976B1 (en) | 2019-12-04 | 2023-07-19 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
-
2021
- 2021-09-03 CN CN202180065297.8A patent/CN116157148A/zh active Pending
- 2021-09-03 JP JP2023514721A patent/JP2023542492A/ja active Pending
- 2021-09-03 AU AU2021336976A patent/AU2021336976A1/en active Pending
- 2021-09-03 IL IL300947A patent/IL300947A/he unknown
- 2021-09-03 MX MX2023002439A patent/MX2023002439A/es unknown
- 2021-09-03 WO PCT/US2021/049077 patent/WO2022051629A1/en active Application Filing
- 2021-09-03 CA CA3193746A patent/CA3193746A1/en active Pending
- 2021-09-03 EP EP21778670.6A patent/EP4208196A1/en active Pending
- 2021-09-03 TW TW110132913A patent/TW202218669A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN116157148A (zh) | 2023-05-23 |
WO2022051629A1 (en) | 2022-03-10 |
TW202218669A (zh) | 2022-05-16 |
WO2022051629A9 (en) | 2022-05-12 |
IL300947A (he) | 2023-04-01 |
JP2023542492A (ja) | 2023-10-10 |
EP4208196A1 (en) | 2023-07-12 |
AU2021336976A1 (en) | 2023-03-23 |
CA3193746A1 (en) | 2022-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002439A (es) | Composiciones immunogénicas y usos de las mismas. | |
MX2019009839A (es) | Celulas eritroides funcionalizadas. | |
PH12020500241A1 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
CR20220240A (es) | Inhibidores de ras | |
MX2022005360A (es) | Inhibidores de ras. | |
MX2022005359A (es) | Inhibidores de ras. | |
MX2023001292A (es) | Mimeticos de hepcidina conjugados. | |
PH12020551261A1 (en) | Il-15 conjugates and uses thereof | |
MX2021000965A (es) | Composiciones que comprenden polirribonucleotidos circulares y usos de estas. | |
MX2020008542A (es) | Composiciones y métodos para el suministro de proteínas membranales. | |
MX2022002633A (es) | Mimeticos de hepcidina conjugada. | |
MX2021013581A (es) | Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
MX2022014161A (es) | Vacunas contra sars-cov-2. | |
MX2022007981A (es) | Derivados de polieter, usos y metodos para hacer los mismos. | |
WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
MX2022014607A (es) | Composiciones inmunogenicas y usos de las mismas. | |
MX2022007391A (es) | Compuestos activos frente a receptores nucleares. | |
PH12020550217A1 (en) | Nutrient-spore formulations and uses thereof | |
MX2023008423A (es) | Anticuerpos anti-gremlin1 novedosos. | |
MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
WO2018175740A8 (en) | Anti-tmeff1 antibodies and antibody drug conjugates | |
MX2023002482A (es) | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
PH12018502139A1 (en) | Phosphaplatin liquid formulations |